News
VTVT
17.01
-2.80%
-0.49
Weekly Report: what happened at VTVT last week (0630-0704)?
Weekly Report · 5d ago
Weekly Report: what happened at VTVT last week (0623-0627)?
Weekly Report · 06/30 12:13
Weekly Report: what happened at VTVT last week (0616-0620)?
Weekly Report · 06/23 12:02
Tracking Baker Brothers Portfolio - Q1 2025 Update
Seeking Alpha · 06/18 01:14
Weekly Report: what happened at VTVT last week (0609-0613)?
Weekly Report · 06/16 12:12
vTv Therapeutics Holds 2025 Annual Stockholders Meeting
TipRanks · 06/12 20:56
vTv Therapeutics to Participate in the H.C. Wainwright “HCW@Home” Series
Barchart · 06/11 07:00
Weekly Report: what happened at VTVT last week (0602-0606)?
Weekly Report · 06/09 12:14
Weekly Report: what happened at VTVT last week (0526-0530)?
Weekly Report · 06/02 12:27
Weekly Report: what happened at VTVT last week (0519-0523)?
Weekly Report · 05/26 12:26
vTv Therapeutics Appoints New CFO Amidst Phase 3 Trial
TipRanks · 05/19 20:52
vTv Therapeutics appoints Michael Tung as CFO
Seeking Alpha · 05/19 13:10
vTv Therapeutics appoints Tung as CFO
TipRanks · 05/19 13:10
vTv Therapeutics Appoints Michael Tung As EVP And CFO, Effective Immediately
Benzinga · 05/19 13:04
VTV THERAPEUTICS APPOINTS MICHAEL TUNG, M.D., MBA, TO CHIEF FINANCIAL OFFICER AS COMPANY REINITIATES PHASE 3 TRIAL OF ORAL T1D ADJUNCTIVE THERAPY TO INSULIN
Reuters · 05/19 13:00
Press Release: vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin
Dow Jones · 05/19 13:00
Weekly Report: what happened at VTVT last week (0512-0516)?
Weekly Report · 05/19 12:12
vTv Therapeutics Highlights Cadisegliatin’s Potential for Diabetes
TipRanks · 05/16 13:28
Analysts Offer Insights on Healthcare Companies: vTv Therapeutics (VTVT) and Precision BioSciences (DTIL)
TipRanks · 05/16 12:10
Buy Rating for vTv Therapeutics: Promising Potential of Cadisegliatin in Type 1 Diabetes Treatment
TipRanks · 05/16 10:17
More
Webull provides a variety of real-time VTVT stock news. You can receive the latest news about Vtv Therapeutics through multiple platforms. This information may help you make smarter investment decisions.
About VTVT
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its product pipeline includes TTP399, TTP273, HPP737 and HPP593. The lead product candidate, cadisegliatin (TTP399), is an orally administered, small-molecule, liver-selective glucokinase activator (GKA) that is a potential adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). HPP737 is an orally administered, non-central nervous system (non-CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and offers the potential for an improved tolerability profile and efficacy over commercially available PDE4 inhibitors. TTP273 is an oral, small molecule, glucagon-like peptide 1 (GLP-1) receptor agonist being evaluated for the treatment of type 2 diabetes mellitus. Its product pipeline also includes Azeliragon and HPP3033.